Delving into the Latest Updates on Shanghai Qiangsheng Pharmacy Co. Ltd. with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Neoplasms

Infectious Diseases

Bispecific antibody

Prophylactic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Infectious Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Bispecific antibody	1
Prophylactic vaccine	1

Top 5 Target	Count

SARS-CoV-2 S protein	1
CD123 x TCRGV9	1

主要目的：第 1 部分：评价受试制剂盐酸西替利嗪片10 mg 与市售制剂盐酸西替利嗪片 10 mg（仙特明®盐酸西替利嗪片10 mg - UCB Farchim SA, Switzerland）在空腹条件下的生物等效性。第 2 部分：评价受试制剂盐酸西替利嗪片10 mg 与市售制剂盐酸西替利嗪片10 mg（仙特明®盐酸西替利嗪片10 mg - UCB Farchim SA, Switzerland）在餐后条件下的生物等效性。次要目的：评价盐酸西替利嗪的受试制剂和参比制剂在空腹（第 1 部分）和餐后（第 2 部分）条件下的安全性。

[Translation]

Primary objectives: Part 1: To evaluate the bioequivalence of the test formulation of cetirizine hydrochloride tablets 10 mg with the commercial formulation of cetirizine hydrochloride tablets 10 mg (Zyrtec® Cetirizine Hydrochloride Tablets 10 mg - UCB Farchim SA, Switzerland) under fasting conditions. Part 2: To evaluate the bioequivalence of the test formulation of cetirizine hydrochloride tablets 10 mg with the commercial formulation of cetirizine hydrochloride tablets 10 mg (Zyrtec® Cetirizine Hydrochloride Tablets 10 mg - UCB Farchim SA, Switzerland) under fed conditions. Secondary objectives: To evaluate the safety of the test and reference formulations of cetirizine hydrochloride under fasting (Part 1) and fed (Part 2) conditions.

Start Date13 Nov 2023

Sponsor / Collaborator

Shanghai Qiangsheng Pharmacy Co. Ltd.

100 Clinical Results associated with Shanghai Qiangsheng Pharmacy Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Qiangsheng Pharmacy Co. Ltd.

Login to view more data

5

Literatures (Medical) associated with Shanghai Qiangsheng Pharmacy Co. Ltd.

02 Feb 2016·Oncotarget

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma

Article

Author: Fang, Douglas D. ; Sun, Hongye ; Gu, Qingyang ; Chan, Chi-Chung ; Wang, Hongyang ; Shen, Yuhong ; Xu, Xiaowei ; Wang, Guan ; Qian, Ziliang ; Yang, Shuqun ; Xu, Qiang ; Luo, Chonglin ; Qin, Yuxin ; Chen, Shu-Hui ; Mao, Mao ; Tan, Yexiong

Hepatocellular carcinoma (HCC) is the fifth most common type of cancers worldwide. However, current therapeutic approaches for this epidemic disease are limited, and its 5-year survival rate hasn't been improved in the past decades. Patient-derived xenograft (PDX) tumor models have become an excellent in vivo system for understanding of disease biology and drug discovery. In order to identify new therapeutic targets for HCC, whole-exome sequencing (WES) was performed on more than 60 HCC PDX models. Among them, four models exhibited protein-altering mutations in JAK1 (Janus Kinase 1) gene. To explore the transforming capability, these mutations were then introduced into HEK293FT and Ba/F3 cells. The results demonstrated that JAK1S703I mutation was able to activate JAK-STAT (Signal Transducer and Activator of Transcription) signaling pathway and drive cell proliferation in the absence of cytokine stimulation in vitro. Furthermore,the sensitivity to the treatment of a JAK1/2 inhibitor, ruxolitinib, was observed in JAK1S703I mutant PDX model, but not in other non-activating mutant or wild type models. Pharmacodynamic analysis showed that phosphorylation of STAT3 in the Ruxolitinib-treated tumor tissues was significantly suppressed. Collectively, our results suggested that JAK1S703I is an activating mutation for JAK-STAT signaling pathway in vitro and in vivo, and JAK-STAT pathway might represent a new therapeutic approach for HCC treatment. Monotherapy using a more potent and specific JAK1 inhibitor and combinatory therapy should be further explored in JAK1 mutant PDX models.

01 Nov 2015·Natural Product CommunicationsQ4 · MEDICINE

Synergy Effects of Three Plant Extracts on Protection of Gastric Mucosa

Q4 · MEDICINE

ArticleOA

Author: Liu, Tao ; Kong, Yi ; Ni, Guojun ; Wang, Caihui ; Su, Xingli ; Su, Wen

The gastric mucosa protection effect of three natural plant extracts, Hericium erinaceus (HE), Centella asiatica (CA) and Amomum villosum (AV), were evaluated using the indomethacin damage model. Compared with a single extract, a combination of HE/CA/AV, especially with the ratios of 80:10:10, 45:45:10 and 45:10:45, showed significant synergistic effects for protection of the gastric mucosa with gastric ulcer inhibition rates of 97.8 ± 0.7%, 86.5 ± 2.8% and 86.1 ± 3.6%, respectively. Microscopic appearances of the gastric mucosa were carried out to help confirm the results.

18 Aug 2015·Drug DeliveryQ2 · MEDICINE

Cationic polymer-based micro-emulgel with self-preserving ability for transdermal delivery of diclofenac sodium

Q2 · MEDICINE

ArticleOA

Author: Tu, Jiasheng ; Zhang, Tao ; Ouahab, Ammar ; Yang, Chunyu ; Wang, Jue ; Shen, Yan

The objective of the present study was to develop a topical preparation with enhanced skin permeation, high safety and self-preserving ability. Microemulsion (ME) and cationic polymer based micro-emulgel (CPBM) were investigated for the transdermal delivery of diclofenac sodium (DS). Medium-chain triglyceride was selected as the oil phase of ME due to its good solubilization of DS and high safety. Orthogonal test was applied to optimize the formula of ME based on the cumulative skin permeation amount in vitro after preliminary formula test. Chitosan (CS) or polylysine was employed as the cationic polymer in the formula of CPBM. The transdermal delivery of DS was evaluated through in vitro skin permeation test. The results showed that the skin permeation rate of DS from the optimized CPBM (126.17 ± 15.82 μg/cm(2)/h) were 1.86-folds and 5.76-folds higher than that of DS commercial Emulgel and DS control hydrogel, respectively. MEs and the cationic polymer were found to have skin penetration co-enhancing effect when they were combined in the CPBM system. Furthermore, the CPBM showed a good growth inhibition of E. coli and S. aureus. The stability test revealed that the CPBM was stable at room temperature and 4 °C for a period of three months.

100 Deals associated with Shanghai Qiangsheng Pharmacy Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Qiangsheng Pharmacy Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Ad26.COV2.S.351 ( SARS-CoV-2 S protein )	Coronavirus Infections More	Preclinical
Anti-TRGV9/anti-CD123 bispecific antibody ( CD123 x TCRGV9 )	Acute Myeloid Leukemia More	Preclinical
MD3606 ( hemagglutinin )	Influenza, Human More	Pending
JNJ-4796 ( hemagglutinin )	Influenza A virus infection More	Pending